Video

Bisphosphonates as Antitumor Agents in Breast Cancer

Publish date: January 6, 2012

 

SAN ANTONIO – Dr. Hope S. Rugo, associate editor of The Oncology Report, discusses the use of bisphosphonates as antitumor agents in early-stage breast cancer at the 2011 San Antonio Breast Cancer Symposium.

Recommended Reading

Imiquimod/Abraxane Combo Effective for Skin Mets
Breast Cancer ICYMI
Less Trastuzumab Cardiotoxicity in Beta-Blocker Users
Breast Cancer ICYMI
Pegfilgrastim Costly, Unnecessary in Some Breast Cancer Patients
Breast Cancer ICYMI
Adjuvant Ibandronate: No Gain in Early Breast Cancer
Breast Cancer ICYMI
Program Curbs Shoulder Morbidity Post Breast Cancer
Breast Cancer ICYMI
Cancer Death Rates Continue to Drop
Breast Cancer ICYMI
Do Bisphosphonates Reduce Cancer Risks?
Breast Cancer ICYMI
Anastrozole and Fulvestrant in Hormone Receptor-Positive Breast Cancer
Breast Cancer ICYMI
Community Oncology Podcast - Radiation in breast cancer
Breast Cancer ICYMI
Retrospective Study of Patients with Metastatic Triple-Negative Breast Cancer: Survival, Health Care Utilization, and Cost
Breast Cancer ICYMI